We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$385M
AUM Growth
-$76.2M
Cap. Flow
-$70.4M
Cap. Flow %
-18.28%
Top 10 Hldgs %
44.6%
Holding
124
New
35
Increased
20
Reduced
21
Closed
33

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$16.8M
2
LLY icon
Eli Lilly
LLY
+$15.1M
3
SHPG
Shire pic
SHPG
+$13.7M
4
AMGN icon
Amgen
AMGN
+$13.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.79M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.6M
2
BIIB icon
Biogen
BIIB
+$18M
3
ORA icon
Ormat Technologies
ORA
+$13.3M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.65M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.41M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Technology 4.38%
3 Communication Services 1.71%
4 Consumer Discretionary 1.16%
5 Financials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$40.8B
$30.1M 7.83%
600,200
-125,000
-17% -$6.65M
AGN
2
DELISTED
Allergan plc
AGN
$22M 5.7%
95,000
-5,000
-5% -$1.15M
SHPG
3
DELISTED
Shire pic
SHPG
$21.6M 5.61%
264,539
+75,863
+40% +$13.7M
GILD icon
4
Gilead Sciences
GILD
$162B
$16.1M 4.17%
192,700
+20,000
+12% +$1.77M
LLY icon
5
Eli Lilly
LLY
$1.02T
$15.8M 4.09%
+200,000
New +$15.1M
CELG
6
DELISTED
Celgene Corp
CELG
$15.3M 3.97%
155,000
+55,000
+55% +$5.69M
PFE icon
7
Pfizer
PFE
$143B
$15M 3.9%
449,649
-1,054,000
-70% -$33.6M
AMGN icon
8
Amgen
AMGN
$208B
$12.9M 3.36%
+85,000
New +$13.2M
BIIB icon
9
Biogen
BIIB
$30B
$12.2M 3.17%
50,500
-68,350
-58% -$18M
VTRS icon
10
Viatris
VTRS
$20.4B
$10.8M 2.81%
250,000
-37,827
-13% -$1.67M
ITRN icon
11
Ituran Location and Control
ITRN
$1.09B
$10.4M 2.71%
460,452
-11,132
-2% -$235K
GSK icon
12
GSK
GSK
$104B
$6.39M 1.66%
+318,630
New +$16.8M
BIIB icon
13
PUT
Biogen
BIIB
$30B
$6.05M 1.57%
+250
New +$65.9K
MRK icon
14
Merck
MRK
$322B
$5.76M 1.5%
+104,800
New +$5.58M
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$5.49M 1.42%
1,005,000
+705,000
+235% +$4.93M
CBIO
16
Crescent Biopharma
CBIO
$535M
$5.22M 1.36%
7,181
+3,802
+113% +$2.62M
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$2.45B
$5.14M 1.33%
+105,000
New +$6.79M
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$121B
$4.96M 1.29%
+57,600
New +$4.98M
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
$4.94M 1.28%
42,323
+2,323
+6% +$330K
ACHC icon
20
CALL
Acadia Healthcare
ACHC
$2.76B
$4.87M 1.26%
+1,500
New +$87.7K
AKAO
21
DELISTED
Achaogen Inc
AKAO
$4.76M 1.24%
+1,257,366
New +$4.37M
CRVS icon
22
Corvus Pharmaceuticals
CRVS
$1.12B
$4.58M 1.19%
325,053
+214,132
+193% +$2.89M
AAP icon
23
Advance Auto Parts
AAP
$3.35B
$4.47M 1.16%
27,662
+7,526
+37% +$1.16M
NDRM
24
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.2M 1.09%
258,513
+92,154
+55% +$1.55M
GILD icon
25
CALL
Gilead Sciences
GILD
$162B
$4.17M 1.08%
+500
New +$44.4K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sphera Funds Management held 124 positions worth $385M, down 17% from $461M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $70.4M in Q2 2016, closing 33 positions and reducing 21 holdings. Its most notable exit was Ormat Technologies, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 62% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in GSK worth $6.39M.

  • Sphera Funds Management's largest Q2 2016 buy was GSK: 318,630 shares worth $6.39M.
  • Sphera Funds Management added most to Shire pic in Q2 2016, an estimated $13.7M increase.
  • Sphera Funds Management's biggest Q2 2016 reduction was Pfizer, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited Ormat Technologies in Q2 2016, selling an estimated $13.3M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $385M portfolio in Q2 2016.
  • Sphera Funds Management opened 35 new positions and closed 33 in Q2 2016.
  • Sphera Funds Management's portfolio value fell 17% quarter-over-quarter to $385M.

Based on Sphera Funds Management's 13F filing for Q2 2016, filed 10 Aug 2016.